JNJ-64140284
- Generic Name
- JNJ-64140284
A Study of JNJ-64140284 in Healthy Male Participants
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 33
- Registration Number
- NCT04566926
- Locations
- 🇧🇪
SGS Life Science Services, Antwerpen, Belgium
A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT04033458
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT03693391
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath